13 Sep

JNJ Stock Up 7% in the Past Month: What Drove the Bulls?

WRITTEN BY Sarah Collins

Recent performance of JNJ stock

On September 12, Johnson & Johnson (JNJ) stock closed at $139.36. That was a 0.61% rise from the previous day’s closing price of $138.51. Currently, JNJ stock is trading above its 50-day moving average of $133.29 and below its 200-day moving average of $127.99.

JNJ Stock Up 7% in the Past Month: What Drove the Bulls?

The stock is currently trading ~6% below its 52-week high of $148.32 reported on January 17. Rumors of a Chinese buyout of JNJ’s diabetes care unit for more than $4 billion were circulating in the market at that time.

On May 29, Johnson & Johnson reported that it was scrapping its Phase Ib/II trial for Darzalex for advanced or metastatic NSCLC (non-small cell lung cancer) treatment, which triggered a massive stock decline and a 52-week low of $118.62 that day. Currently, JNJ stock is trading ~17.5% higher than its 52-week low.

Recent events impacting JNJ stock

Over the last month, JNJ stock has risen ~7%. Over the last three months, it has risen ~14%, primarily on key product approvals and launches. However, year-to-date, JNJ stock has fallen ~0.26%.

Johnson & Johnson reported strong Q2 2018 results on July 17, which led to a ~3.5% rise in the stock. But since the company lost some lawsuits related to its talc-based products in July, the stock fell.

Over the past 12 months, JNJ stock has risen ~5.1% compared to ~12% for the Healthcare Select Sector SPDR ETF (XLV), which is reflective of the performance of the US healthcare industry. The broader market rose ~16% in the same period. Over the last year, Johnson & Johnson’s peers Pfizer (PFE), Mylan (MYL), and Abbott Laboratories (ABT) have returned 21%, 12.4%, and 29%, respectively.

In the rest of this series, we’ll look at some key events for JNJ over the last month.

Latest articles

In the week that ended on November 15, natural gas prices fell 3.5% and settled at 2.688 per MMBtu (million British thermal units).

The Dow Jones Index (DIA) and S&P 500 (SPY) are trading at record highs and on Friday the Dow Jones crossed the 28,000 level for the first time.

Goldman Sachs (GS) settled a lawsuit that alleged it rigged bond prices. Also, Deutsche Bank agreed to pay a fine of $15 million to settle a lawsuit.

In the November 15 premarket trading session, Amarin Corporation (AMRN) stock rose more than 7%, caused by the FDA positive decision for Vascepa.

In the November 14 trading session, Aurora Cannabis (ACB) stock fell 12.7% from the previous session during after-hours trading.

Strategy Analytics reported that Apple could lead the 5G smartphone market in 2020, outshining Samsung—the current leader in the global 5G market.